Risk of Premature Cardiovascular Disease vs the Number of Premature Cardiovascular Events

Abstract

Discussion | In women with signs and symptoms of ischemia and nonobstructive CAD, those with prior infarct had a 2.84-fold increased risk of death for up to 8.5 years of follow-up. Ischemia on stress testing was not associated with an increase in risk of mortality in this population of women. Our results may not be generalizable to nonangiographic populations of women or to men. A second limitation is that our classification of women is based on a mixture of stress testing results with different sensitivity and specificity for ischemia and/or infarct. Our findings underscore the need for heightened recognition of an adverse event profile in these women.

Lifetime vs 10-year Cardiovascular Disease Prediction in Young Adults Using Statistical Machine Learning and Deep Learning: The CARDIA Study

“…Our results in a young population (23)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33)(34)(35) years-old at baseline) suggest that ML/DL methods are well suited for meaningful risk prediction in extensively phenotyped large-scale epidemiological cohorts, particularly for 10-year CVD event prediction. RSF and Nnet-survival provided better prediction over standard risk scores and other ML and statistical techniques.…”

Photoplethysmography‐Derived Arterial Stiffness Index Delivered Greater Cardiovascular Prevention Value to Non‐Elderly: A Retrospective Cohort Study Based on UK Biobank

“…However, some limitations of this study merit careful consideration when interpreting the results. First, we have excluded participants younger than 40 years old due to the SCORE2 calculation criteria; nonetheless, the risk of new‐onset CVD is relatively low before age 40 and then steadily increases thereafter [37]. Second, our findings are primarily derived from European populations and therefore require further validation; however, the unprecedented scale of UK biobank reminds us of the critical importance of harnessing wearable technologies for large‐scale disease prevention, particularly in non‐elderly populations.…”

Apolipoprotein B and Cardiovascular Disease: Biomarker and Potential Therapeutic Target

“…Cardiovascular disease remains the leading cause of death worldwide [ 264 ]. Recent data have shown a decline in mortality from CHD in the United States of America, but the rate of decline is decelerating and, in younger adults under age 45, there is a lack of progress in reducing cardiovascular deaths [ 265 , 266 ]. In this younger group, a rise in diabetes mellitus and obesity may be hindering improvement in cardiovascular mortality [ 267 ].…”